Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Theodore G Karrison

Showing results (21-30 of 61) with videos related to

Pageof 7
Sort By:
Investigational New Drugs|January 25, 2008
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemiaOlatoyosi M Odenike, Richard A Larson, Devika Gajria, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 15, 2012
Spleen cells from young but not old immunized mice eradicate large established cancersKarin Schreiber, Ainhoa Arina, Boris Engels, et al.
Cancer Immunology Research|December 14, 2019
Impact of TCR Diversity on the Development of Transplanted or Chemically Induced TumorsKarin Schreiber, Theodore G Karrison, Steven P Wolf, et al.
International Journal of Radiation Oncology, Biology, Physics|May 4, 2010
Outcomes in black patients with early breast cancer treated with breast conservation therapyMichael A Nichols, Loren K Mell, Michael D Hasselle, et al.
Investigational New Drugs|August 4, 2009
Phase II study of sunitinib malate in head and neck squamous cell carcinomaNicholas W Choong, Mark Kozloff, David Taber, et al.
Archives of Internal Medicine|June 24, 2009
Frequency of failure to inform patients of clinically significant outpatient test resultsLawrence P Casalino, Daniel Dunham, Marshall H Chin, et al.
Cancer|January 16, 2019
A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignanciesManish R Sharma, Smita S Joshi, Theodore G Karrison, et al.
Cancer|January 28, 2022
Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testingNatalie M Reizine, Keith Danahey, Tien M Truong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2015
Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and CilengitidePeter H O'Donnell, Sanja Karovic, Theodore G Karrison, et al.
Clinical Lung Cancer|February 22, 2023
Brief Report: Discordance Between Liquid and Tissue Biopsy-Based Next-Generation Sequencing in Lung Adenocarcinoma at Disease ProgressionMisha C Tran, Garth W Strohbehn, Theodore G Karrison, et al.
Pageof 7

Showing results (21-30 of 61) with videos related to

Sort By:
Pageof 7
Investigational New Drugs|January 25, 2008
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemiaOlatoyosi M Odenike, Richard A Larson, Devika Gajria, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 15, 2012
Spleen cells from young but not old immunized mice eradicate large established cancersKarin Schreiber, Ainhoa Arina, Boris Engels, et al.
Cancer Immunology Research|December 14, 2019
Impact of TCR Diversity on the Development of Transplanted or Chemically Induced TumorsKarin Schreiber, Theodore G Karrison, Steven P Wolf, et al.
International Journal of Radiation Oncology, Biology, Physics|May 4, 2010
Outcomes in black patients with early breast cancer treated with breast conservation therapyMichael A Nichols, Loren K Mell, Michael D Hasselle, et al.
Investigational New Drugs|August 4, 2009
Phase II study of sunitinib malate in head and neck squamous cell carcinomaNicholas W Choong, Mark Kozloff, David Taber, et al.
Archives of Internal Medicine|June 24, 2009
Frequency of failure to inform patients of clinically significant outpatient test resultsLawrence P Casalino, Daniel Dunham, Marshall H Chin, et al.
Cancer|January 16, 2019
A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignanciesManish R Sharma, Smita S Joshi, Theodore G Karrison, et al.
Cancer|January 28, 2022
Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testingNatalie M Reizine, Keith Danahey, Tien M Truong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2015
Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and CilengitidePeter H O'Donnell, Sanja Karovic, Theodore G Karrison, et al.
Clinical Lung Cancer|February 22, 2023
Brief Report: Discordance Between Liquid and Tissue Biopsy-Based Next-Generation Sequencing in Lung Adenocarcinoma at Disease ProgressionMisha C Tran, Garth W Strohbehn, Theodore G Karrison, et al.
Pageof 7